Skip to Main content Skip to Navigation

Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development

Abstract : Despite being the least abundant immunoglobulin G in human plasma, IgG4 are used therapeutically when weak effector functions are needed. The increase in engineered IgG4-based antibodies on the market led us to study the patent landscape of IgG4 Fc engineering, i.e., patents claiming modifications in the heavy chain. Thirty-seven relevant patent families were identified, comprising hundreds of IgG4 Fc variants focusing on removal of residual effector functions (since IgG4s bind to FcγRI and weakly to other FcγRs), half-life enhancement and IgG4 stability. Given the number of expired or soon to expire major patents in those 3 areas, companies developing blocking antibodies now have, or will in the near future, access to free tools to design silenced, half-life extended and stable IgG4 antibodies.
Keywords : Fc IgG4 engineering patents
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-tours.archives-ouvertes.fr/hal-02425290
Contributor : Valérie Gouilleux <>
Submitted on : Monday, December 30, 2019 - 11:44:08 AM
Last modification on : Friday, January 10, 2020 - 4:12:21 PM

Links full text

Identifiers

Collections

Citation

Christophe Dumet, Jérémy Pottier, Valérie Gouilleux-Gruart, Herve Watier. Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development. mAbs, Taylor & Francis, 2019, 11 (8), pp.1341-1350. ⟨10.1080/19420862.2019.1664365⟩. ⟨hal-02425290⟩

Share

Metrics

Record views

46